This site contains promotional content intended for UK Healthcare Professionals and other relevant decision makers | Not a HCP? Visit our Public Site.
Adverse Event reporting can be found at the bottom of the page | Prescribing Information for the relevant medicine can be found adjacent to the below content and/or in the footer below.
WELCOME TO CONFIDENCE, EXTENDED
EYLEA 8 mg is the first and only anti-VEGF in nAMD and DMO that allows for extensions up to Q20*, with a safety profile comparable to EYLEA 2 mg. So you can confidently extend treatment intervals to help optimise your clinic's capacity.
EYLEA 114.3 mg/mL is indicated in adults for the treatment of neovascular (wet) age-related macular degeneration (nAMD) and visual impairment due to diabetic macular oedema (DMO).
Instructions for use and handling of EYLEA 8 mg in patients with nAMD and DMO
Key steps for administering EYLEA 8 mg
Using aseptic technique, attach the filtre needle supplied in the carton to a 1 mL sterile Luer Lock syringe.
Disclaimer: These instructions are not complete. For full instructions, please download the instructions for use (IFU) card below and refer to the EYLEA 114.3 mg/mL Summary of Product Characteristics.
*Following 3 monthly loading doses, intervals can be extended to Q16, dependent on visual and/or anatomic outcomes, and subsequently to Q20 (e.g. with a T&E regimen) if visual and/or anatomic outcomes are stable. Consult the SmPC for full posology.
Prescribing information for EYLEA® (aflibercept) can be found here.
Abbreviations
DMO, diabetic macular oedema. MoA, mechanism of action. nAMD, neovascular (wet) age-related macular degeneration. Q16, every 16 weeks. Q20, every 20 weeks. T&E, treat and extend. VEGF, vascular endothelial growth factor.
PP-EYL-GB-2325 | August 2024
- Referencesexpand_less
- 1Korobelnik J-F. Intravitreal aflibercept 8 mg injection in patients with neovascular age-related macular degeneration: 48-week results from the Phase 3 PULSAR trial. Retina Society. 2–5 November 2022. Pasadena, USA. Oral presentation.
- 2Do D. Aflibercept 8 mg for diabetic macular edema: 48-week results from the Phase 2/3 PHOTON trial. ARVO. 23–27 April 2023. Palo Alto, USA. Oral presentation.
- 3Lanzetta P, et al. Intravitreal aflibercept 8 mg injection in patients with neovascular age-related macular degeneration: 60-week and 96-week results from the Phase 3 PULSAR trial. EURETINA. 5–8 October 2023. Amsterdam, The Netherlands. Oral presentation.
- 4Wykoff CC. Aflibercept 8 mg for diabetic macular edema: 96-week results from the Phase 2/3 PHOTON trial. EURETINA. 5–8 October 2023. Amsterdam, The Netherlands. Oral presentation.
- 5EYLEA® 114.3 mg/mL Summary of Product Characteristics.